Intermedin inhibits norepinephrine-induced contraction of rat seminal vesicle

P. F. Wong, M. P. L. Cheung, WS O,, F. Tang,

1Departments of Physiology, LKS Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong, China

2Department of Anatomy, LKS Faculty of Medicine, University of Hong Kong, Pokfulam, Hong Kong, China

3Centre of Growth, Reproduction and Development, LKS Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong, China

4Centre of Heart, Brain and Healthy Aging, LKS Faculty of Medicine, University of Hong Kong, Pokfulam, Hong Kong, China

Intermedin inhibits norepinephrine-induced contraction of rat seminal vesicle

P. F. Wong1, M. P. L. Cheung2, WS O2,3, F. Tang1,4*

1Departments of Physiology, LKS Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong, China

2Department of Anatomy, LKS Faculty of Medicine, University of Hong Kong, Pokfulam, Hong Kong, China

3Centre of Growth, Reproduction and Development, LKS Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong, China

4Centre of Heart, Brain and Healthy Aging, LKS Faculty of Medicine, University of Hong Kong, Pokfulam, Hong Kong, China

ARTICLE INFO

Article history:

Received 9 December 2013

Received in revised form 5 February 2014

Accepted 6 February 2014

Available online 20 September 2014

IMD

ADM-2

Seminal vesicle

Muscle contraction

Objective: To study the effect of inter medin(IMD) on smooth muscle of rat seminal vesicles including the specific receptors and the signal pathways involved.Methods: The contraction of the seminal vesicle in response to norepinephrine (NE) and ADM2/IMD was studied by the organ bath method. The effects of antagonists for calcitonin gene related peptide (CGRP), adrenomedullin (ADM) and IMD receptors, and inhibitors of nitric oxide synthase, [L-NGNitroarginine Methyl Ester, L-NAME) and cAMP-dependent protein kinase (PKA), KT5720] were also investigated. The first overshoot, amplitude, frequency and basal tone were measured. Results: There is no significant effect of IMD on the initial overshoot, frequency and the basal tone in the seminal vesicle contraction. Only the amplitude of the contraction induced by NE was inhibited by IMD. The IMD inhibitory actions on amplitude were completely blocked by hADM22-52 and L-NAME, but not by hCGRP8-37 or KT5720. Furthermore, the action was diminished by IMD17-47. Conclusion: The results demonstrated that the inhibitory action of IMD on NE-induced seminal vesicle contraction was mediated via the ADM receptor(s) and the nitric oxide production pathway, partially by the IMD receptor, but not by the CGRP receptor and the cAMPPKA pathway.

1. Introduction

Intermedin (IMD)/adrenomedulin 2(ADM-2), a novel peptide discovered in 2004[1,2], belongs to the calcitonin (CT)/ calcitonin gene-related peptide (CGRP) superfamily. The peptide was named intermedin because it was first discovered in the intermediate lobe of the pituitary[2]. Prepro-IMD was found to be a 146-150-amino-acid peptide and the C-terminal of its prepro-peptide showed about 30% and <20% sequence identity with adrenomedullin (ADM) and CGRP respectively. Three biologically active forms of IMD peptides can be produced from prepro-IMD after posttranslational modification. They are a 47-amino-acid IMD (IMD1-47), a shorter 40-amino-acid IMD (IMD8-47) and the longest 53-amino-acid IMD (IMD1-53). They are generated by proteolytic cleavage at their different respective N-terminal sites[3].

Since IMD shares about 30% and 20% sequence homology with ADM and CGRP respectively, it shows vasodilatory effects with the action mediated by CGRP and ADM receptors[2-4]. ADM and CGRP preferentially bind to the calcitonin receptorlike receptor (CRLR)/specific receptor activity modifying proteins (RAMP) 2&3 and CRLR/RAMP1 receptor complexes respectively[5,6] while IMD shows similar affinity to all the 3 types of CRLR receptor complexes[2]. However, IMD may preferentially activate the ADM2 receptor[7]. Much work has been done recently in our laboratory on the roles of ADM in reproduction [8-12]. Wong et al. has also reported

the expression of IMD mRNA, its peptide, and the receptor component in female reproductive organs including the ovary, oviduct and the uterus[13]. They also studied the inhibitory effects of IMD on uterine contraction and the signal pathways involved[13]. The inhibitory effects of ADM on norepinehrineinduced contraction of rat seminal vesicle have also been documented[14], which suggested that ADM plays a possible role in the control of seminal vesicle muscle contraction during ejaculation. All the evidence supports the hypothesis that IMD, may also play a role in the regulation of seminal vesicle contraction during ejaculation. The effects of IMD on NE-induced contraction of rat seminal vesicle was therefore investigated, together with the receptors and some signal pathways involved.

2. Materials and methods

2.1. Animals

Male Sprague-Dawley rat of 9-10 weeks was obtained from the Laboratory Animal Unit, Univeristy of Hong Kong Faculty of Medicine. The rats were killed by an overdose of sodium pentobarbitone. All the procedures were approved by the Committee on the Use of Live Animals for Teaching and Research (University of Hong Kong).

2.2. Immunohistochemistry

Paraffine sections of seminal vesicles were used for immunohistochemical (IHC) staining for IMD. The streptavidin-biotin-peroxidase complex method was used which involves the incubation of the sections with primary antibody specific to IMD (cat. no. H-010-52, Phoenix Pharmaceuticals, California, USA), a biotylinated secondary antibody that reacts with primary antibody, enzyme labeled streptavidin, and DAB substrate chromogen. The Rabbit ABC staining system kit (SC-2018, Santa Cruz Biotechnology, Inc. Santa Cruz, California, USA) was used.

2.3. Organ bath experiment

The coagulating glands and blood vessels connecting to the seminal vesicles were carefully removed before the seminal vesicles were dissected out. The seminal vesicles were washed free of fluid by Kreb’s solution injected from the syringe and were placed into the oxygenated Kreb’s solution containing 118 mM NaCl, 4.8 mM KCl, 1 mM MgSO4, 1.15 mM NaH2PO4, 15 mM NaHCO3, 10.5 mM glucose, and 2.5 mM CaCl2. They were then tied with silk threads to holder electrodes in a 10 mL organ bath attached to a force transducer (Model 7 Polygraph, Grass, Massachusetts, USA). The tissues were perfused with Kreb’s solution equilibrated with 95% O2-5% CO2at 37 ℃. A tension of 0.1 g was applied and the tissues were allowed to stabilize for 50 minutes before the addition of drugs. To examine the effect of IMD on the NE induced contraction of seminal vesicles, the tissues were treated with 10 μM NE plus/ minus 100 nM human IMD1-53 (cat no. 010-08, Pheonix Pharmaceuticals , California, USA) after equilibration for 50 minutes and the amplitudes of contractions were recorded for 20 minutes. For studying the receptors, the tissues were pre-incubated with the receptor antagonists for 30 minutes after 20 minutes equilibration and before the addition of NE and IMD. Receptor antagonists such as hADM22-52, hCGRP8-37 and IMD17-47 (cat. no. 010-04, 015-06 and 010-57, Phoenix Pharmaceuticals, California, USA), and enzyme inhibitors including KT5720 (cat. no. K3761, Sigma, St Louis, Missouri, USA) and L-NAME, (cat. no. 483125, Calbiochem, EMD Biosciences, San Diego, California, USA) were used in this study. Each treatment had its control from the same rat treated with 10 μM NE only. The basal tone, frequency, the first overshoot and contraction amplitude were measured from the period 2 to 12 mins after addition of NE and expressed as the percentage change compared to the control sample.

2.4. Statistics

The percentage changes were expressed as mean ± SEM and the statistical significance was assessed by Oneway ANOVA followed by the Least Significant Difference (LSD) post-hoc test. The homogeneity of variances was also tested and Dunnett’s T3 tests were used instead of LSD when P<0.05. All statistical analyses were performed using IBM SPSS Statistics 21 (Chicago, USA) and statistic significance was indicated when P was equal to or less than 0.05.

3. Results

3.1. Immunohistochemistry

IMD immunoreactivity was localized to the epithelial cells and some fibroblasts inside the epithelium (Figure 1).

Figure 1. Immunocytochemical study of IMD in the rat seminal vesicles.Positive IMD immunoreactivity localized to the epithelial cells and fibrobalsts (A) as compared to the negative control section (B).

3.2. Organ bath experiment

The addition of NE (10 μM) caused an increase in the contraction (first overshoot) of seminal vesicle (Figure 2A). When IMD was added at the same time, there are no significant differences in basal tone, frequency and first overshoot in both 10 nM IMD and 100 nM IMD groups relative to control group treated with NE alone (the control group, Table 1). However, there was a significant decrease in contraction amplitude in both 10 nM IMD (P<0.01) and 100 nM IMD (P<0.001) groups compared with the control and also a significant decrease in the 100 nM IMD group versus the 10 nM group (Table 1). These suggest that there was a dose response of IMD in inhibiting NE-induced contraction. The decrease in contraction amplitude in response to 100 nM IMD was not decreased by hCGRP8-37 or KT5720 pre-treatment. On the other hand, the inhibitory action of IMD was completely abrogated by hADM22-52 and greatly reduced by L-NAME (Figure 3). A significant reduction in % decrease in amplitude (P<0.001) was observed. There was still a significant decrease (P<0.01) in contraction amplitude in IMD17-47 group relative to the control group in spite of a significant reduction (P<0.01 compared with 100 nM IMD group (Figure 3). This suggests that the action of IMD was only partially blocked by IMD17-47. In all these studies, the receptor antagonists and enzyme inhibitors alone had no effect on the NE-stimulated contraction.

Figure 2. Tracings of seminal vesicle contraction induced by NE and the effects of receptor antagonists and KT5720 and L-NAME IMD dose-dependemtly inhibited muscle contracton induced by NE in seminal vesicles (A-C). The increase in contraction amplitude was inhibited by 100 nM IMD (C). hADM22-52 (D), but not hCGRP8-37 (E), completely blocked the inhibitory effect of IMD. IMD17-47 also partially blocked the inhibitory effect of IMD (F). KT5720, did not block the inhibitory effect of IMD (G), unlike L-NAME (H).

Figure 3. Inhibiton of amplitude response to NE by IMD and the effects of receptor antagonists and KT5720 and L-NAME. Data presented as mean ± SEM. (n=5, except group hCGRP8-37 (n=4) and group IMD17-47 (n=7).*P<0.01,**P<0.001 vs. NE;#P<0.01,##P<0.001 vs. 100 nM IMD.

Table 1Dose response to IMD in inhibiting NE-stimulated muscle contraction in the seminal vesicle.

4. Discussion

An inhibitory effects of IMD on contractile response of smooth muscle has been reported for the uterus[13]. Together with, the positive staining for the peptide, the inhibitory effect of IMD on seminal vesicle contraction here suggests that IMD may be involved in the regulation of seminal vesicle contraction.

Our findings from studies using receptor antagonists and enzyme inhibitors suggests that IMD inhibits seminal vesicle contraction mostly by a specific ADM receptor and via NO pathway, and the CGRP receptor and cAMP-dependent protein kinase pathway are not involved. In the smooth muscles of the vasculature, the NO pathway was involved in the vasodilatory actions of IMD[4, 14-15]. cAMP has been reported to be involved in IMD vasorelaxant actions on the coronary artery[14] and aortic rings[16] but not on pulmonary artial rings[17]. The result also suggests that the specific IMD receptor antagonist may only partially block the IMD receptor. These findings are similar to those for IMD in uterine contraction in that in both organs the NO pathway was involved but the PKA pathway was not[13]. They differ from the finding in the uterus in the relative importance of the receptors involved. In the uterus, both CGRP and ADM receptor

antagonists partially blocks while the IMD receptor antagonist completely blocks the inhibitory actions of IMD[13].

These results are different from the previous study of inhibitory effects of ADM where the inhibition of smooth muscle contraction was prevented by hCGRP8-37 and was not mediated by the NO pathway[18]. These findings suggest that different pathways and receptors mediate the effect of different peptides such as ADM (via CGRP receptor) and IMD (via ADM1, ADM2 receptor and specific IMD receptor). Besides various inhibitors[19-21] and ADM[18], IMD may be a possible therapeutic agent for inhibiting seminal vesicle contraction to delay ejaculaton stimulated by the sympathetic system.

Conflict of interest statement

We declare that we have no conflict of interest.

Acknowledgment

This study was supported by a grant from the Elaine GCF Tso Memorial Fund, LKS Faculty of Medicine, HKU.

[1] Chang CL, Roh J, Hsu SY. Intermedin, a novel calcitonin family peptide that exists in teleosts as well as in mammals: a comparison with other calcitonin/intermedin family peptides in vertebrates. Peptides 2004; 25(10): 1633-1642.

[2] Roh J, Chang CL, Bhalla A, Klein C, Hsu SY. Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activitymodifying protein receptor complexes. J Biol Chem 2004; 279(8): 7264-7274.

[3] Bell D, McDermott BJ. Intermedin (adrenomedullin-2): a novel counter-regulatory peptide in the cardiovascular and renal systems. Br J Pharmacol 2008; 153 Suppl 1: S247-S262.

[4] Yang JH, Pan CS, Jia YX, Zhang J, Zhao J, Pang YZ, et al. Intermedin1-53 activates L-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. Biochem Biophys Res Commun 2006; 341(2): 567-572.

[5] McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998; 393(6683): 333-339.

[6] Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 2002; 54(2): 233-246.

[7] Hong Y, Hay DL, Quirion R, Poyner DR. The pharmacology of adrenomedullin 2/intermedin. Br J Pharmacol 2012; 166(1): 110-120.

[8] Chan YF, Tang F, O WS. Adrenomedullin in the rat testis. II: Its production, actions on inhibin secretion, regulation by folliclestimulating hormone, and its interaction with endothelin 1 in the Sertoli cell. Biol Reprod 2008a; 78(4): 780-785.

[9] Chan YF, O WS, Tang F. Adrenomedullin in the rat testis. I: Its production, actions on testosterone secretion, regulation by human chorionic gonadotropin, and its interaction with endothelin 1 in the leydig cell. Biol Reprod 2008b; 78(4): 773-779.

[10] Li YY, O WS, Tang F. Effect of aging on the expression of adrenomedullin and its receptor component proteins in the male reproductive system of the rat. J Gerontol A Biol Sci Med Sci 2007; 62(12): 1346-1351.

[11] Li YY, Li L, Hwang IS, Tang F, O WS. Coexpression of adrenomedullin and its receptors in the reproductive system of the rat: effects on steroid secretion in rat ovary. Biol Reprod 2008; 79(2): 200-208.

[12] Liao SB, Ho JC, Tang F, O WS. Adrenomedullin increases ciliary beat frequency and decreases muscular contraction in the rat oviduct. Reproduction 2011; 141(3): 367-372.

[13] Wong CW, O WS, Tang F. Intermedin in rat uterus: changes in gene expression and peptide levels across the estrous cycle and its effects on uterine contraction. Reprod Biol Endocrinol 2013; 11: 13.

[14] Grossini E, Molinari C, Mary DA, Uberti F, Caimmi PP, Vacca G. Intracoroary intermedin 1-47 augments cardiac perfusion and function in anesthetized pigs: role of calcitonin receptors and beta-adrenoceptor-mediated nitric oxide release. J Appl Physiol 2009; 107(4) 1037-1050.

[15] Jolly L, March JE, Kemp PA, Bennett T, Cardiner SM. Mechanisms involved in the regional haemodynamic effects of intermedin (adrenomedullin 2) compared with adrenomedullin in conscious rats. Br J Pharmacol 2009; 157(8) 1502-1513.

[16] Pan CS, Yang JH, Cai DY, Hao J, Gerns H, Yang J, et al. Cardiovascular effects of newly discovered peptide intermedin/ adrenomedullin 2. Peptides 2005; 26(9) 1640-1646.

[17] Kandilci HB, Gumusel B, Lippton H. Inermedin/adrenomedullin-2 (IMD/AM2) relaxes rat main pulmonary arterial rings via cGMP-dependent pathways: role of nitric oxide and large conductance calcium-activated potassium channels (BK(Ca)). Peptides 2008; 29(8) 1321-1328.

[18] Liao SB, O WS, Tang F. Adrenomedullin inhibits norepinephrineinduced contraction of rat seminal vesicle. Urology 2012; 80(1): 224.e1-5.

[19] Birowo P, Uckert S, Kedia GT, Sonnenberg JE, Thon WF, Rahardjo D, et al. Characterization of the effects of various drugs likely to affect smooth muscle tension on isolated human seminal vesicle tissue. Urology 2010; 75(4): 974-978.

[20] Birowo P, Uckert S, Kedia GT, Sonnenberg JE, Sandner P, Thon WF, et al. Exposure of human seminal vesicle tissue to phosphodiesterase (PDE) inhibitors antagonizes the contraction induced by norepinephrine and increases production of cyclic nucleotides. Urology 2010b; 76(6): 1518.e1-6.

[21] Giuliano F, Bernabe J, Droupy S, Alexandre L, Allard J. A comparison of the effects of tamsulosin and alfuzosin on neurally evoked increases in bladder neck and seminal vesicle pressure in rats. BJU Int 2004; 93:605-608.

ment heading

10.1016/S2305-0500(14)60022-1

*Corresponding author: Corresponding author: Professor F. Tang, Department of Physiology, LKS Faculty of Medicine, 21 Sassoon Road, Pokfulam, Hong Kong, China. Tel: (852) 2819 9269

Fax: (852) 2855 9730

E-mail: ftang@hku.hk

This study was supported by a grant from the Elaine GCF Tso Memorial Fund, LKS Faculty of Medicine, HKU.